ERYTECH and Pancreatic Cancer Treatment [transcript][audio]

Guest: Iman El-Hariry, M.D., Ph.D.

Presenter: Neal Howard

Guest Bio: Iman El-Hariry, M.D., Ph.D. has served as Chief Medical Officer of  ERYTECH Pharma, Inc., since June 2015. Prior to her appointment as Chief Medical Officer, she served as President of Azure Oncology Consulting from July 2014 to June 2015 and also assisted us in a consulting role from November 2014 to June 2015. Dr. El-Hariry served as Vice President of Clinical Research at Synta Pharmaceuticals from November 2010 to July 2014 and as Global Head of Oncology at Astellas Pharma, Inc. from June 2009 to July 2010. From 2001 to 2009, she served as Director of Clinical Development, Oncology at Glaxo Smith Kline. Dr. El-Hariry is a licensed oncologist with an M.D. from Alexandria Medical School (Egypt) and a Ph.D. in Cancer Research from Imperial College of Science and Medicine (United Kingdom).

Segment Overview: Dr. Iman El-Hariry, PhD, CMO of Erytech discusses positive results for Erytech’s Phase 2B study of lead product Eryaspase (GRASPA®) in pancreatic cancer.


Leave a Reply

You must be logged in to post a comment.